The outgoing chief executive of the UK’s drugs regulator has said that the country’s “preferred option” is to continue working with the European regulator after Brexit – although there are
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
